Progyny raises 2025 guidance after second-quarter revenue rises 9.5% to $332.9 million
Progyny reported second-quarter 2025 revenue of $332.9 million, up 9.5% from a year earlier, and net income of $17.1 million, or $0.19 per diluted share, compared with $0.17 a year earlier. The company raised its full-year 2025 guidance, now projecting revenue of $1.235 billion to $1.270 billion, but the expiration of a large client's transition agreement on June 30 removes that client's contribution in the second half. For shareholders, the higher outlook reflects stronger member engagement, while Adjusted EBITDA margin slipped to 17.4% from 17.9%.
Key points
- Q2 2025 revenue was $332.9 million, up 9.5% from $304.1 million; excluding the large client, revenue rose 18%.
- Net income was $17.1 million, or $0.19 per diluted share, versus $16.5 million, or $0.17, in Q2 2024.
- Full-year 2025 revenue guidance is $1.235 billion to $1.270 billion, and net income guidance is $52.3 million to $58.9 million.
- As of June 30, 2025, the company had cash and marketable securities of $305.1 million and no debt; a $200 million revolving credit facility was entered into after quarter end.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.